GO
Loading...

Gilead Sciences Inc

More

  • Midday Glance: Biotechnology companies Thursday, 16 Oct 2014 | 1:21 PM ET

    Amgen Inc. fell $1.85 or 1.4 percent, to $129.05. Biogen Idec fell $2.23 or. 7 percent, to $303.46. Celgene Corp. fell$. 18 or. 2 percent, to $86.37.

  • Early Glance: Biotechnology companies Thursday, 16 Oct 2014 | 11:35 AM ET

    Amgen Inc. fell $1.81 or 1.4 percent, to $129.09. Biogen Idec fell $2.69 or. 9 percent, to $303.00. Celgene Corp. fell $1.56 or 1.8 percent, to $84.99.

  • BOSTON, Oct 16- Some of Wall Street's biggest names are licking their wounds as October lives up to its reputation as one of the market's roughest months. Morgan Stanley strategists said this week that their model portfolio through Monday had trailed the S&P by 3.6 percentage points due to bad bets on technology stocks, including GT Advanced Technologies, the...

  • Final Glance: Biotechnology companies Wednesday, 15 Oct 2014 | 6:07 PM ET

    Amgen Inc. fell $1.30 or 1.0 percent, to $130.90. Biogen Idec rose $4.11 or 1.4 percent, to $305.69. Celgene Corp. rose$. 07 or. 1 percent, to $86.55.

  • The first, Esbriet, was developed by InterMune Inc, which Switzerland- based Roche Holding AG agreed to buy for $8.3 billion in August, banking largely on the treatment's potential. The agency's decision marks a crucial milestone in the management of the disease, which affects about 100,000 people in the United States. Roche's drug, known generically as...

  • Midday Glance: Biotechnology companies Wednesday, 15 Oct 2014 | 1:17 PM ET

    Amgen Inc. fell $2.15 or 1.6 percent, to $130.05. Biogen Idec rose $5.29 or 1.8 percent, to $306.87. Celgene Corp. fell $1.36 or 1.6 percent, to $85.12.

  • Early Glance: Biotechnology companies Wednesday, 15 Oct 2014 | 10:46 AM ET

    Amgen Inc. fell $1.56 or 1.2 percent, to $130.64. Biogen Idec rose $1.69 or. 6 percent, to $303.27. Celgene Corp. fell$. 90 or 1.0 percent, to $85.58.

  • Final Glance: Biotechnology companies Tuesday, 14 Oct 2014 | 6:03 PM ET

    Amgen Inc. fell $1.36 or 1.0 percent, to $132.20. Biogen Idec fell$. 16 or. 1 percent, to $301.58. Celgene Corp. fell $1.00 or 1.1 percent, to $86.48.

  • Citigroup and Domino's are big market movers Tuesday, 14 Oct 2014 | 4:37 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:. Johnson& Johnson, down $2.11 to $97.01. Citigroup Inc., up $1.57 to $51.47.

  • Midday Glance: Biotechnology companies Tuesday, 14 Oct 2014 | 1:42 PM ET

    Amgen Inc. fell$. 09 or. 1 percent, to $133.47. Biogen Idec rose $3.62 or 1.2 percent, to $305.36. Celgene Corp. rose$. 66 or. 8 percent, to $88.14.

  • Irish tax changes may cost U.S. groups billions Tuesday, 14 Oct 2014 | 11:15 AM ET

    *Brussels investigating schemes involving minimal tax. LONDON, Oct 14- Ireland's plan to close a "Double Irish" tax loophole could cost U.S. companies including Apple and Google billions of dollars, although a new break and pressure to tackle tax avoidance elsewhere means they are unlikely to decamp. Ireland has been an attractive base for U.S. multinationals for...

  • Early Glance: Biotechnology companies Tuesday, 14 Oct 2014 | 10:27 AM ET

    Amgen Inc. fell$. 92 or. 7 percent, to $132.64. Biogen Idec fell $5.23 or 1.7 percent, to $296.51. Celgene Corp. fell $1.41 or 1.6 percent, to $86.07.

  • *JPMorgan falls, Citigroup climbs after results. Citigroup, up 3.2 percent to $51.48, was the biggest boost to the benchmark S&P index after the bank posted better-than-expected quarterly results and said it would pull out of consumer banking in 11 markets. But JPMorgan Chase shares lost 0.9 percent to $57.61, after the biggest U.S. bank posted third-quarter...

  • UPDATE 2-J&J beats forecasts, helped by hepatitis drug Tuesday, 14 Oct 2014 | 9:55 AM ET

    Oct 14- Johnson& Johnson reported better-than-expected quarterly earnings, fueled by surging sales of its new drug for hepatitis C that are expected to evaporate in coming months due to competition from a more potent and convenient combination treatment. Sales of the J&J drug, called Olysio and approved by U.S. regulators in November, reached $796 million in...

  • J&J hikes 2014 forecast for a third time Tuesday, 14 Oct 2014 | 8:18 AM ET

    Johnson& Johnson lifted its 2014 earnings forecast for a third time on Tuesday, fueled in part by revenue gains from its new blockbuster hepatitis C treatment Olysio. J&J's higher forecast came a couple days after the Food and Drug Administration approved Harvoni, a pill from Gilead Sciences Inc. that can cure the most common form of hepatitis C without the...

  • Drop in energy stocks stymies market rebound Tuesday, 14 Oct 2014 | 1:06 AM ET

    Encouraging earnings from Domino's Pizza, Citigroup and others helped drive the modest rally, which began strong and tapered somewhat toward the end of the day. LONG WAY BACK: Stocks are coming off their worst week in more than two years. THE QUOTE: Joe Peta, managing director at Novus Partners, characterized Tuesday's turnaround as a bounce back after a rush to...

  • Midday Glance: Biotechnology companies Monday, 13 Oct 2014 | 1:19 PM ET

    Amgen Inc. fell $1.25 or. 9 percent, to $136.14. Biogen Idec fell $3.26 or 1.0 percent, to $311.88. Celgene Corp. fell $1.31 or 1.4 percent, to $89.62.

  • Early Glance: Biotechnology companies Monday, 13 Oct 2014 | 10:29 AM ET

    Amgen Inc. fell$. 88 or. 6 percent, to $136.51. Biogen Idec fell $5.01 or 1.6 percent, to $310.13. Celgene Corp. fell $1.50 or 1.6 percent, to $89.43.

  • Oct 10- U.S. regulators on Friday approved a new hepatitis C pill from Gilead Sciences Inc, which said it will charge $94,500 for an improved 12- week course of treatment to rid patients of the liver-destroying viral infection. "Unfortunately, we believe that the price being demanded is still inappropriately high for a product targeting such a large group of...

  • Oct 10- U.S. regulators on Friday approved a new hepatitis C pill from Gilead Sciences Inc, which said it will charge $94,500 for an improved 12- week course of treatment to rid patients of the liver-destroying viral infection. "We believe the price is very reasonable and attractive to payors as it is a significant discount to previous regimens that cost upwards...